Osteoarthritis Drug Discovery Services

Osteoarthritis (OA) has emerged as a prevalent chronic disease worldwide, with its incidence increasing in lockstep with the aging population. It is a multifaceted disease characterized by progressive cartilage degeneration, synovial membrane inflammation, and joint structural alterations. Osteoarthritis is also the leading cause of long-term disability, underscoring the urgent need for effective treatments that can mitigate its impact.

Fig. 1 Structural changes in aged and osteoarthritis knee joints. (O'Brien MS and McDougall JJ, 2019)

CD BioSciences offers customized atherosclerosis drug discovery services, with specialized expertise in aging-related mechanisms that drive disease pathogenesis.

Osteoarthritis Drug Discovery Targeting Aging Mechanisms

Drug discovery targeting cartilage degradation in aging

Cartilage degradation, a hallmark of osteoarthritis, is exacerbated by the aging process. We help clients discover drugs that can promote cartilage repair and regeneration. Our experts are actively exploring various pharmacological agents capable of mimicking growth factor activity or enhancing the expression of growth factors like transforming growth factor-beta (TGF-β).

Drug discovery targeting subchondral bone changes in aging

Subchondral bone alterations, including sclerosis and cyst formation, contribute to the progression of osteoarthritis. We help clients investigate the role of drugs in regulating bone remodeling, aiming to maintain subchondral bone integrity and prevent the development of osteoarthritis.

Drug discovery targeting inflammaging in osteoarthritis

Chronic low-grade inflammation is a known contributor to osteoarthritis. We help clients develop drugs targeting key inflammatory pathways, such as the NF-κB pathway, to reduce the inflammatory burden in osteoarthritis joints. We also explore the efficacy of naturally derived drugs, such as curcumin and resveratrol, which possess anti-inflammatory properties.

Drug discovery targeting cellular senescence in osteoarthritis

We help clients develop drugs that remove senescent cells and modulate the senescence-associated secretory phenotype (SASP), which reduces joint inflammation and degradation.

Mechanism Analysis of Anti-Aging Drugs in Osteoarthritis

CD BioSciences provides a comprehensive mechanism analysis of anti-aging drugs in osteoarthritis. Our approach helps select drug candidates that are not only effective but also safe for use.

• Drug mechanism of action analysis services. We help clients analyze the molecular pathways underlying the effects of anti-aging drugs on cartilage health, subchondral bone integrity, and inflammation. For example, our experts analyze the role of growth factors, including TGF-β and insulin-like growth factor (IGF-1), in anti-aging drug formulations to support cartilage repair. We also assess how anti-aging drugs influence bone density and microarchitecture, which are critical for joint stability.
• Drug efficacy evaluation services. Utilizing in vitro and in vivo models, we assess the pharmacological effects of anti-aging drugs on osteoarthritis, including cartilage degradation and inflammatory responses.

CD BioSciences is dedicated to providing osteoarthritis drug discovery services, with a particular focus on the aging mechanisms underlying the disease. If you are interested in our services, please feel free to contact us or make an online inquiry.

References

1. Zhang XX, et al. Aging, Cell Senescence, the Pathogenesis and Targeted Therapies of Osteoarthritis. Front Pharmacol, 2021, 12: 728100.
2. O'Brien MS, McDougall JJ. Age and frailty as risk factors for the development of osteoarthritis. Mech Ageing Dev, 2019 Jun;180:21-28.